Protein kinase TEC has been demonstrated to activate ERK within the hepatocyte growth factor signaling pathway [45], while inhibition of MEK/ERK phosphorylation is partly responsible for the anti-tumor activity of the kinase inhibitor sorafenib [46]. The gene discussed is MAP2K7; the disease is neoplasm.